Appetite stimulation
With rising prevalence of both conditions globally, identifying effective pharmacological interventions remains a major clinical priority
Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR Jr, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG , Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J
In diabetes trials, patients often lost weight while using tirzepatide, but the main approved goal of Mounjaro remains blood sugar control
Reference List Jesse Smith MD
A recent study from the University of Copenhagen raises new concerns about GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, highlighting potential bone density loss